“The Protein Detection Quantification Market is projected to grow at a CAGR of 6.5% from 2024 to 2031, reaching a value of USD 3.8 billion by 2031.”North America dominates the market, accounting for YY% of the global share.
Key metrics include increasing R&D activities in proteomics and rising prevalence of chronic diseases. The protein detection quantification market is expanding rapidly, owing to advances in proteomic technology and a growing emphasis on personalised therapy. The use of artificial intelligence and machine learning into protein analysis instruments improves accuracy and efficiency, hence pushing market growth.
Market Trend: Shift towards multiplex protein detection and quantification technologies for comprehensive proteome analysis
The protein detection quantification market is witnessing a significant shift towards multiplex technologies that allow simultaneous detection and quantification of multiple proteins. This trend is driven by the growing demand for comprehensive proteome analysis in various research and clinical applications. Multiplex assays offer advantages such as reduced sample volume requirements, increased throughput, and cost-effectiveness.
In 2023, the multiplex protein detection segment accounted for YY% of the market share, with a projected CAGR of 7.2% from 2024 to 2031. This growth is fueled by the increasing adoption of multiplex technologies in drug discovery and biomarker identification processes.
Recent industry developments include the launch of advanced multiplex protein detection platforms. For instance, a leading life sciences company introduced a high-plex protein detection system in 2023, capable of analyzing up to 1,000 proteins simultaneously from a single sample, catering to the growing demand for large-scale proteomics studies.
Market Driver: Rising prevalence of chronic diseases and growing focus on biomarker discovery
The rising prevalence of chronic diseases, combined with an increased emphasis on biomarker research, is driving the adoption of protein detection and quantification methods. Proteins serve as biomarkers for a variety of disorders, therefore accurate detection and quantification are critical for early diagnosis and treatment monitoring.
According to the World Health Organisation, chronic diseases account for 71% of all deaths worldwide each year. This has resulted in an increase in research activity targeted at discovering new protein biomarkers for illness diagnosis and prognosis. In 2023, global spending in biomarker discovery research will amount USD 5.2 billion, with protein-based biomarkers accounting for 45% of the total studies.
Furthermore, the pharmaceutical sector is increasingly using protein detection and quantification tools in drug research and development. In 2023, the pharmaceutical industry accounted for 40% of the protein detection quantification market, with adoption rates increasing by 12% year on year.
Market Restraint: High costs associated with advanced protein detection and quantification technologies limiting adoption in smaller research facilities
The high costs associated with advanced protein detection and quantification methods limit market growth, especially among smaller research centres and academic institutions. Advanced mass spectrometry systems and high-throughput protein analysis platforms can cost between USD 200,000 and USD 1 million, depending on their capabilities and specifications.
Furthermore, operational expenditures such as maintenance, reagents, and qualified staff contribute to the overall cost of protein analysis. The annual operational cost of a typical proteomics laboratory can be 10% to 15% of the initial equipment expenditure.
This cost hurdle has slowed uptake in smaller research centres, with only 25% of academic laboratories having access to modern protein quantification tools by 2023. To solve this issue, some manufacturers are producing more cost benchtop protein analysis systems with basic functionality to meet the needs of budget-conscious laboratories. However, these lower-cost solutions frequently sacrifice sensitivity and throughput, limiting their usefulness in complicated proteomics studies.
Immunological methods dominate the protein detection quantification market, accounting for YY% of the global market share.
Immunological approaches have emerged as the leading technology in the protein detection quantification industry, accounting for 38% of the global market share. This technology's appeal arises from its excellent specificity, sensitivity, and versatility in identifying and measuring a diverse spectrum of proteins across multiple sample types.
Immunological procedures, such as enzyme-linked immunosorbent tests (ELISA), Western blotting, and immunohistochemistry, have various benefits, including ease of use, quick findings, and the capacity to detect low-abundance proteins. These factors have contributed to their broad use in scientific, clinical, and industrial settings.
Over the last two years, immunological approaches have experienced a 15% increase in use in the pharmaceutical and biotechnology industries. This expansion is being driven by the technology's success in identifying target proteins, discovering biomarkers, and assessing therapeutic efficacy. Immunological approaches have become crucial in drug discovery and development due to their capacity to generate highly specific antibodies against novel protein targets.
The clinical diagnostics area has also embraced immunological approaches, with adoption rates increasing by 10% year after year. This increase is attributable to the technology's capacity to deliver precise and timely protein measurement for illness diagnosis, prognosis, and treatment monitoring. Immunological assays are commonly used to identify cancer biomarkers, cardiovascular disease indicators, and infectious disease antigens.
Recent advances in immunological approaches have centred on increasing sensitivity and multiplexing abilities. A leading manufacturer has launched a novel multiplexed immunoassay technology that can quantify up to 100 proteins from a single sample with femtogram-level sensitivity. This innovation responds to the expanding need for high-throughput, multi-analyte protein analysis in both academic and clinical settings.
North America leads the protein detection quantification market, driven by robust R&D infrastructure and significant investments in life sciences research.
North America dominates the worldwide protein detection quantification market, with over YY% of the market share. The region's leadership position is largely due to its well-established research infrastructure, significant investments in life sciences, and the presence of major pharmaceutical and biotechnology corporations.
The United States, in particular, is at the forefront of proteomics research and technological advancement. This rise is being fuelled by increased government financing for proteomics research, as well as the rising prevalence of chronic diseases, which is boosting demand for better diagnostic tools.
The National Institutes of Health (NIH) recently launched a new funding effort to help researchers develop breakthrough protein detection and quantification tools. This effort, with a USD 50 million budget over five years, seeks to accelerate advances in proteomics research and clinical applications. The pharmaceutical and biotechnology sectors account for 45% of total market value in the region.
Canada has seen a considerable increase in proteomics research activity, particularly in the area of cancer biomarker identification. The country's Genomics Enterprise (CGEn) recently announced a large-scale proteomics effort, investing CAD 10 million in cutting-edge protein quantification methods. This endeavour is projected to accelerate growth in the Canadian protein detection quantification market in the coming years.
The protein detection quantification market is characterised by fierce rivalry among leading competitors vying for market share through technical innovation and strategic partnerships. Leading businesses such as Thermo Fisher Scientific, Bio-Rad Laboratories, and Merck KGaA account for over YY% of the global market share.
Thermo Fisher Scientific has maintained its market leadership with a YY% market share, owing to its extensive line of protein analysis products and strong global presence. The company's recent acquisition of a proteomics software provider has helped it improve its position in the data analysis sector.
Bio-Rad Laboratories has concentrated on increasing its market share through product innovation and strategic collaborations. In 2023, the business introduced a unique automated western blotting technology, expanding its offering in the immunological techniques segment.
Merck KGaA has highlighted its competence in reagents and consumables for protein detection and quantification. The company's recent release of a high-sensitivity protein measurement kit has been warmly appreciated by academic and pharmaceutical researchers.
Emerging firms like Quanterix Corporation and Olink Proteomics are gaining interest for their novel protein detection technology. These firms are working to develop ultra-sensitive and high-multiplex protein analysis technologies in order to gain a foothold in the booming field of precision medicine and biomarker development.
Looking ahead, the competitive environment is projected to shift, with a greater emphasis on integrated proteomics solutions, artificial intelligence-driven data analysis, and the development of point-of-care protein detection technologies for clinical use.
The Protein Detection Quantification market is poised for a dramatic transition, fuelled by technical developments and the growing importance of proteomics in different sectors of life sciences. As medicine and biotechnology become increasingly personalised and precision-based, there will be a greater demand for precise, sensitive, and high-throughput protein analysis methods.
One emerging trend is the use of microfluidics and nanotechnology in protein detection devices. This convergence enables the creation of miniaturised, highly sensitive protein analysis devices that can identify and quantify proteins in extremely small sample volumes. Early users of these nanoscale protein detection technologies have reported breakthroughs in single-cell proteomics and exosome analysis, paving the way for biomarker identification and disease diagnoses.
Another notable development is the growing interest in spatial proteomics, which seeks to better understand protein localisation and interactions inside cells and tissues. We predict an increase in demand for protein detection and quantification technologies that preserve spatial information, such as imaging mass spectrometry and in situ sequencing. This developing industry offers numerous potential for market growth and technological innovation.
The transition to data-driven proteomics is also driving advancements in protein detection and quantification technology. We're seeing the rise of integrated platforms that combine superior technology with powerful bioinformatics tools, allowing researchers to obtain deeper insights from large proteome datasets. This approach is likely to transform the competitive landscape, favouring organisations that can provide complete solutions, including sample preparation, protein analysis, and data interpretation.
As the market matures, we anticipate a confluence of genomes and proteomics technologies, resulting in the creation of multi-omics platforms capable of offering a full perspective of biological systems. This comprehensive approach to molecular analysis is likely to drive the next generation of discoveries in life sciences and create new applications for protein detection and quantification technologies.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Merck KGaA
PerkinElmer, Inc.
Abcam plc
Becton, Dickinson and Company
Cell Signaling Technology, Inc.
Promega Corporation
Qiagen N.V.
Agilent Technologies, Inc.
Quanterix Corporation
Olink Proteomics AB
April 2024: Thermo Fisher Scientific introduces a new high-throughput protein quantification platform that combines sophisticated mass spectrometry with AI-driven data processing to improve accuracy and speed.
In February 2024, Bio-Rad Laboratories collaborated with a renowned academic institution to develop revolutionary antibody-based protein detection technologies for liquid biopsy applications in cancer diagnosis.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Thermo Fisher Scientific Inc.
5.2. Bio-Rad Laboratories, Inc.
5.3. Merck KGaA
5.4. PerkinElmer, Inc.
5.5. Abcam plc
5.6. Becton, Dickinson and Company
5.7. Cell Signaling Technology, Inc.
5.8. Promega Corporation
5.9. Qiagen N.V.
5.10. Agilent Technologies, Inc.
5.11. Quanterix Corporation
5.12. Olink Proteomics AB (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards multiplex protein detection and quantification technologies for comprehensive proteome analysis
6.1.2. Integration of microfluidics and nanotechnology in protein detection systems
6.1.3. Growing interest in spatial proteomics
6.2. Market Drivers
6.2.1. Rising prevalence of chronic diseases and growing focus on biomarker discovery
6.2.2. Increasing R&D activities in proteomics research
6.2.3. Advancements in protein detection and quantification technologies
6.3. Market Restraints
6.3.1. High costs associated with advanced protein detection and quantification technologies limiting adoption in smaller research facilities
6.3.2. Complexity in data interpretation and analysis
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Colorimetric Assays
7.2. Immunological Methods
7.3. Chromatography
7.4. Mass Spectrometry
7.5. Spectrophotometry
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Drug Discovery and Development
8.2. Clinical Diagnosis
8.3. Others
9. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Pharmaceutical Companies
9.2. Academic Research Institutes
9.3. Contract Research Organizations
9.4. Biotechnology Companies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Technology:
Colorimetric Assays
Immunological Methods
Chromatography
Mass Spectrometry
Spectrophotometry
By Application:
Drug Discovery and Development
Clinical Diagnosis
Others
By End-User:
Pharmaceutical Companies
Academic Research Institutes
Contract Research Organizations
Biotechnology Companies
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
